MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
Follow MMED
Alert me
MiniMed Group, Inc. (MMED) EV/EBITDA
MiniMed Group, Inc. has no meaningful EV/EBITDA: its trailing twelve-month EBITDA is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Jul 2026 | 0.0× | — |
| Jan 2026 | 0.0× | — |
| Jul 2025 | 0.0× | — |
| Jan 2025 | 0.0× | — |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PLSE Pulse Biosciences, Inc compare | n/m |
| MMED MiniMed Group, Inc. | n/m |
| NVST Envista Holdings Corporation compare | 10.3× |
| STVN Stevanato Group S.p.A. compare | 11.3× |
| BLCO Bausch + Lomb Corporation compare | 14.6× |
| MMSI Merit Medical Systems, Inc. compare | 15.5× |
| ICUI ICU Medical, Inc. compare | 16.0× |
| TFX Teleflex Incorporated compare | 35.7× |
| ATRC AtriCure, Inc. compare | 83.7× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on MMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement